Certara (NASDAQ:CERT) Posts Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Certara missed quarterly expectations: EPS was $0.08 versus the $0.09 consensus, while revenue of $93.27 million fell short of the $98.09 million estimate and declined 10.8% year over year.
• Growth was mixed and profitability weakened: Software bookings rose 9% and the company reaffirmed full-year revenue guidance, but services bookings fell 6%, adjusted EBITDA margin guidance was cut to 29%–31%, and Certara reported a $6.1 million continuing-operations net loss.
• Management is pursuing cost savings and shareholder returns: A workforce reduction affecting about 5% of employees is expected to save approximately $13 million annually, while the board authorized an additional $50 million share-repurchase program. Shares fell 15.9%, and analysts’ consensus rating remained “Hold.”

Certara (NASDAQ:CERT - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01), FiscalAI reports. The business had revenue of $93.27 million during the quarter, compared to analysts' expectations of $98.09 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm's quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.07 earnings per share.

Here are the key takeaways from Certara's conference call:

• Second-quarter revenue grew 1% to $93.3 million, with software revenue up 4% and services revenue down 3%. Management reaffirmed full-year revenue growth guidance of 0%–4%, or $367 million–$382 million on a continuing-operations basis.
• Software bookings increased 9% in the quarter and trailing-12-month software bookings rose 8%, supported by Simcyp, Phoenix and Pinnacle 21. The company also reported a 27% year-over-year increase in pipeline and expects software revenue to reach at least the high end of its annual growth range.
• Certara is implementing a new commercial model, appointing Julien Perrier as Chief Commercial Officer and emphasizing specialist-led services sales. A May workforce reduction affecting about 5% of employees is expected to generate approximately $13 million in annualized savings, helping offset stranded costs from the divestiture and fund AI investment.
• Services bookings declined 6% in the second quarter, and management expects full-year services revenue to be at or below the low end of its 0%–4% growth range. Adjusted EBITDA margin guidance was reduced to 29%–31%, while the company posted a $6.1 million continuing-operations net loss versus $1.5 million of income in the prior-year quarter.
• The board authorized an additional $50 million share-repurchase program after Certara completed a prior $100 million authorization. Management also highlighted growing cloud adoption, AI-enabled product development and partnerships—including NVIDIA—as longer-term growth opportunities.

Certara Stock Down 15.9%

Shares of NASDAQ CERT opened at $6.88 on Tuesday. The stock has a market cap of $1.07 billion, a PE ratio of -69.17 and a beta of 1.44. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. Certara has a 12-month low of $4.45 and a 12-month high of $13.88. The company has a 50-day moving average of $6.36 and a 200 day moving average of $6.57.

Institutional Investors Weigh In On Certara

Large investors have recently made changes to their positions in the stock. AQR Capital Management LLC acquired a new position in Certara during the first quarter worth $259,000. Goldman Sachs Group Inc. raised its holdings in shares of Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company's stock worth $2,267,000 after acquiring an additional 90,724 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company's stock valued at $2,965,000 after acquiring an additional 35,954 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company's stock valued at $2,743,000 after purchasing an additional 40,463 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Certara by 29.3% in the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company's stock valued at $1,089,000 after purchasing an additional 21,099 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CERT shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Certara in a report on Friday, May 29th. Barclays dropped their target price on shares of Certara from $8.00 to $6.50 and set an "equal weight" rating on the stock in a research report on Tuesday, May 12th. Morgan Stanley decreased their price target on shares of Certara from $11.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 12th. Stephens reduced their target price on Certara from $10.00 to $9.00 and set an "overweight" rating for the company in a report on Tuesday, May 12th. Finally, BMO Capital Markets decreased their target price on Certara from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $8.85.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company's offerings are divided into software tools and consulting services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source